FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type R	esponses)																	
1. Name and Address of Reporting Person * SEIDENBERG BETH C				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) 2750 SAND HILL ROAD			3. Date of Earliest Transaction (Month/Day/Year) 06/08/2017								Officer (give	title below)		er (specify be	low)			
(Street) MENLO PARK, CA 94025				4. If Amendment, Date Original Filed(Month/Day/Year)								_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(State)	(Zip)				Table	I - N	on-Der	ivativ	e Secur	ities /	Acquired	Disnosed	of or Renet	ficially Own	ed	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Yea	r) any		2d 3. Trans Code (Instr. 8		ansaction		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)			red 5. Amount of S (D) Owned Follow Transaction(s)		Securities Beneficially ring Reported		6. Ownership Form:	7. Nature of Indirect Beneficial	
				(M	onth/Da	y/Yea		ode	V	Amo) or D)	(Inst	or (I)			Ownershi (Instr. 4)	
Common Stock		06/08/2017					A		5,000 (1)) A		\$ 0 13,6	13,689			D		
Common Stock													1,82	1,822,228			I	See Footnote
Common Stock													54,4	54,422			I	See Footnote
Common Stock												197	197			I	See Footnote	
Common Stock													197				I	See Footnote
Reminder: Repo	ort on a separa	ate line for each o	class of securities	benet	ficially o	wned	directly		Perso	ns wl	n are no	ot red		respond	unless the	tion contai	ned SEG	C 1474 (9-02
			Table II										cially Owr	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Ye		te, if	4.		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form of Derivation Securi Direct or Indi	ttive Owne ty: (Instr. (D) rect		
					Code	v	(A)	(D)	Date Exerci	isable	Expirati Date	ion	Title	Amount or Number of Shares				
NonQualified Stock Option (Right to Buy)		06/08/2017			A		21,500		Ú	<u>6)</u>	06/08/	2024	Commo	n 21,500	\$ 0	21,500	D	

Reporting Owners

Describes Ossess Nove / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
SEIDENBERG BETH C							
2750 SAND HILL ROAD	X						
MENLO PARK, CA 94025							

Signatures

/s/ Ava Hahn, Attorney-in-Fact	06/12/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units shall vest on June 8, 2018, subject to the Reporting Person's continuous service.
- The shares are directly held by Kleiner Perkins Caufield & Byers XV, LLC ("KPCB XV"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The (2) managing member of KPCB XV is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has
- The shares are directly held by KPCB XV Founders Fund, LLC ("KPCB XV FF"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing (3) member of KPCB XV FF is XV Associates. The voting and dispositive control over the shares is shared by individual managing members of XV Associates, none of whom has veto power.
- (4) Shares held by the Michael J. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
- (5) Shares held by the Samuel B. Seidenberg Irrevocable Trust, established July 1, 2013, of which the Reporting Person is a trustee.
- (6) The option shall vest on June 8, 2018, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Beth Seidenberg, M.D. (the "Reporting Person") hereby authorizes and designates Susan Biglieri, Ava Hahn and Scott Ryles (each, an "Authorized Signatory") to prepare and file on behalf of the Reporting Person individually, or jointly together with the other reporting persons, any and all reports, notices, communications and other documents (including, but not limited to, reports on Schedule 13D, Schedule 13G, Form 13-F, Form 3, Form 4 and Form 5) that the Reporting Person may be required to file with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (together with the implementing regulations thereto, the "Act") and the Securities Exchange Act of 1934, as amended (together with the implementing regulations thereto, the "Exchange Act") (collectively, the "Reports") with respect to the Reporting Person's ownership of, or transactions in, securities of any entity whose securities are beneficially owned (directly or indirectly) by the Reporting Person (collectively, the "Companies"). The Reporting Person hereby further authorizes and designates each Authorized Signatory to perform any and all other acts, which in the opinion of such Authorized Signatory may be necessary or incidental to the performance of the foregoing powers herein granted.

The authority of each Authorized Signatory under this Document with respect to the Reporting Person shall continue until the Reporting Person is no longer required to file any Reports with respect to the Reporting Person's ownership of, or transactions in, the securities of the Companies, unless earlier revoked in writing. The Reporting Person acknowledges that each Authorized Signatory is not assuming any of the Reporting Person's responsibilities to comply with the Act or the Exchange Act.

June 2, 2017

/s/ Beth Seidenberg Beth Seidenberg, M.D.